shutterstock_1364456177_madamf
madamF / Shutterstock.com
14 February 2022Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Americas
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Generics
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Americas
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Generics
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.
Americas
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.